Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Βιοτεχνολογία

Ms. Sarah  Cavanaugh

Senior Vice President of Corporate Affairs & Administration

Mr. Freddy A. Jimenez Esq.

Senior Vice President & General Counsel

Dr. Tibor  Keler Ph.D.

Founder, Chief Scientific Officer & Executive Vice President

Ms. Elizabeth  Crowley

Chief Product Development Officer & Senior Vice President

Dr. Ronald A. Pepin

Chief Business Officer & Senior Vice President

Mr. Anthony S. Marucci M.B.A.

Founder, President, Chief Executive Officer & Director

Mr. Sam  Martin

Senior Vice President, Chief Financial Officer, Secretary & Treasurer

Dr. Diane C. Young M.D.

Senior Vice President & Chief Medical Officer

Dr. Margo  Heath-Chiozzi M.D.

Senior Vice President of Regulatory Affairs

Prof. Joseph P. Schlessinger Ph.D.

Co-Founder & Member of Scientific Advisory Board

Όνομα	Κεφαλαιοποίηση αγοράς
Sorrento Therapeutics, Inc.	0M
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
CytoTools AG	0M
Hofseth BioCare ASA	0M
Shanghai Haohai Biological Technology Co., Ltd.	0M
Purple Biotech Ltd.	0M

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.Λίστα ανταγωνιστών

Κύριοι ανταγωνιστές